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of therapy. A review of clinical literature was conducted. Utility
was estimated from a survey of the general public using a time-
trade-offmethodology. Costswere calculated from the perspective
of the UK National Health Service. Future costs and beneﬁts were
discounted at 3.5%. RESULTS: When overall survival (OS) was
assumed to be equal, treatment with alemtuzumab instead of
chlorambucil increased lifetime cost per patient from £10,957 to
£17,938 and increased QALYs per patient from 1.59 to 1.96 at a
cost of £18,788 per QALY gained. When OS was allowed to vary
to reﬂect differences in progression free survival the cost perQALY
fell to £14,604. Findings were most sensitive to the cost of the
interventions, response rate and duration at ﬁrst line. CONCLU-
SIONS:This study found that in theUK, the cost perQALYgained
with ﬁrst-line alemtuzumab therapy over chlorambucil is £18,788
in high-risk (17p-) CLL patients.
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OBJECTIVES: To conduct a cost utility analysis of docetaxel-
doxorubicin (AT) vs standard doxorubicin-cyclophosphamide
(AC) chemotherapy as neoadjuvant therapy for patients with
locally advanced breast cancer in Poland. METHODS: We devel-
oped a cost-utility Markov model from a public payers’ perspec-
tive (National Health Fund), using clinical data from published
sources, Polish cost data, and a lifetime horizon.RESULTS: Based
on a systematic review, only one randomized clinical trial
was included in the comparison: AT (docetaxel 75 mg/m2 +
doxorubicin 50 mg/m2, every 3weeks,mean number of cycles 5.5)
vs AC (doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2,
every 3 weeks, mean number of cycles 5.5). Average costs of the
treatment for locally advanced breast cancer (including neoadju-
vant chemotherapy, treatment of serious adverse events, surgery,
additional post-operative therapy, health state monitoring, local
and distant relapse treatment and palliative care) were 53,677
PLN for AT and 33,716 PLN for AC. Treatment effects (per
patient) were 8,258 QALY and 9,081 LYG for AT and 7,191
QALYand 8, 075LYG forAC. ICER for theAT vsAC comparison
were 18,729 PLN/QALY and 19,842 PLN/LYG. The ICER values
were below the acceptable threshold for very cost-effective treat-
ment in Poland (27 000 PLN). CONCLUSIONS: The docetaxel
regimen is more effective and more expensive in the neoadjuvant
treatment of patients with locally advanced breast cancer com-
pared with AC chemotherapy. ICERs are below the acceptable
threshold, therefore the docetaxel therapy can be considered a
cost-effective treatment for locally advanced BC in Poland.
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OBJECTIVES: Rituximab has recently received European
approval for its use in combination with any chemotherapy. The
aim of this study is to evaluate the cost-effectiveness of rituximab
added to the most commonly used chemotherapy regimens, per-
formed from the Spanish National Health System perspective.
METHODS: We developed a Markov model based on 3 random-
ized controlled clinical trials comparing the addition of ritux-
imab to chemotherapy regimens of CVP; MCP or CHOP vs
chemotherapy alone, in patients with advanced follicular lym-
phoma. Progression-free survival (PFS) and overall survival were
the endpoints evaluated in these trials. Rates of disease progres-
sion were derived from the PFS Kaplan-Meier curves, mortality
rates were obtained from the Scotland-Newcastle Lymphoma
Group database and Spanish age-speciﬁc mortality tables;
resource consumption data was based on a local expert panel
questionnaire and patient utilities to account for quality of life
were applied to the PFS and progressed health states. Medication
and supportive care costs, and quality-adjusted life years
(QALYs) were estimated over 10 years and discounted at 3.5%.
Univariate and probabilistic sensitivity analysis were performed.
RESULTS: The addition of rituximab to chemotherapy increased
QALYs by 0.795, 1.129 and 0.971 years for CVP, MCP and
CHOP, respectively, compared to chemotherapy alone. The
incremental cost per QALY gained was €10,190, €6,092 and
€7,855, for CVP, MCP and CHOP, respectively. The incremental
cost per life year gained was €10,168, €6,348 and €8,190, for
CVP, MCP and CHOP, respectively. Sensitivity analyses indicated
the results were robust, and most sensitive to the duration of
treatment effect and time horizon. CONCLUSIONS: The addi-
tion of rituximab to any of the chemotherapy regimens evalu-
ated, was estimated to increase quality-adjusted life expectancy,
and be a highly cost-effective treatment option for patients with
advanced follicular lymphoma.
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OBJECTIVES: To assess the cost-effectiveness of treating, in an
observational setting, ﬁrst-line Chronic Lymphocytic Leukaemia
(CLL) patients in the USA with Rituximab, Fludarabine and
Cyclophosphamide (R-FC) versus FC alone (Tam et al., 2008).
METHODS: A 3-state semi-Markov model was developed with
rates of disease progression obtained from the Progression Free
Survival curves (R-FC n = 300; FC n = 108, 6 year median
follow-up) using the best ﬁt (Weibull) function, and rates of
death in the PFS and progressed states based on background
mortality and observed CLL mortalities respectively. Published
utility values of 0.8 and 0.6 were applied to PFS and progressed
health states and no treatment beneﬁt was assumed beyond the
observational period. Costs were estimated using Medicare reim-
bursed rates, MS-DRGs for CLL and published drug prices, and
include the cost of administration and adverse events. Costs (in
USD) and quality-adjusted life-years (QALYs) were estimated
over a lifetime horizon (30 years) and discounted at 3% per
annum. RESULTS: Average lifetime health service costs per
patient were $51,694, and $29,192 for R-FC and FC respec-
tively. Life expectancy was estimated as 9.9 years for R-FC and
7.7 years for FC. Average QALYs for R-FC and FC were 7.3 and
5.5 years respectively. The incremental cost-effectiveness ratio for
R-FC compared to FC was $10,291 per life year gained and
$12,382 per QALY gained. The modeled results were robust to
sensitivity analyses assessing the uncertainty about costs and
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